Soma, Tomoya

写真a

Affiliation

School of Medicine, Department of Dentistry and Oral Surgery ( Shinanomachi )

Position

Senior Assistant Professor (Non-tenured)/Assistant Professor (Non-tenured)

Related Websites

External Links
Scopus Paper Info  
Paper Count: 33 Citation Count: 334 h-index: 9

Click to view the Scopus page. The data was downloaded from Scopus API in June 21, 2026, via http://api.elsevier.com and http://www.scopus.com .

Page Top ▲

Career 【 Display / hide 】

  • 2025.04
    -
    Present

    Keio University Hospital, Department of Dentistry and Oral Surgery, Chief Physician

  • 2023.04
    -
    Present

    Keio University Hospital, Center for Perinatal and Pediatric Care

  • 2024.10
    -
    Present

    Keio University School of Medicine, Department of Dentistry and Oral Surgery, Senior Assistant Professor / Lecturer (full time)

  • 2021.04
    -
    2024.09

    Keio University School of Medicine, Department of Dentistry and Oral Surgery, Assistant Professor

  • 2018.04
    -
    2020.03

    Keio University, Graduate School of Medicine, Assistant Professor

display all >>

Page Top ▲

Academic Background 【 Display / hide 】

  • 2017.04
    -
    2021.03

    Keio University, Graduate School of Medicine, Keio University

    Graduate School, Completed, Doctoral course

Page Top ▲

Academic Degrees 【 Display / hide 】

  • Ph.D.in Medicine, Keio University, Coursework, 2021.03

    Tooth extraction in mice administered zoledronate increases inflammatory cytokine levels and promotes osteonecrosis of the jaw

Page Top ▲

Licenses and Qualifications 【 Display / hide 】

  • （公社）日本口腔外科学会認定口腔外科指導医, 2024.04

  • （公社）日本化学療法学会認定抗菌化学療法認定歯科医師, 2016.01

  • （公社）日本口腔外科学会認定口腔外科専門医, 2020.04

  • （一社）日本歯科専門医機構認定口腔外科専門医, 2020.04

  • 日本がん治療認定医機構がん治療認定医 （歯科口腔外科）, 2021.04

display all >>

Page Top ▲
 

Research Areas 【 Display / hide 】

  • Life Science / Surgical dentistry

  • Life Science / Tumor biology

Page Top ▲

Research Keywords 【 Display / hide 】

  • Medication-Related OsteoNecrosis of the Jaw (MRONJ)

  • Bone metabolism

  • Osteoclast

  • Patient-dervied xenografts

  • Oral cancer

display all >>

Page Top ▲
 

Books 【 Display / hide 】

Page Top ▲

Papers 【 Display / hide 】

  • Antibacterial silver ion-coated dental implants suppress peri-implantitis in a murine model

    Mana Nasu, Tomoya Soma, Hidetaka Miyashita, Takehito Ouchi, Yoshitaka Kase, Takazumi Yasui, Fuka Homma, Kitaru Suzuki, Takeshi Miyamoto, Hideyuki Okano, Masaya Nakamura, Taneaki Nakagawa, Mamoru Aizawa, Satoru Morikawa

    Scientific Reports (Springer Science and Business Media LLC)   2026.05

    Lead author, Accepted

    　View Summary

    Abstract

    Peri-implantitis, an inflammatory condition caused by bacterial infection around an implant, is currently the leading cause of implant failure. Porphyromonas gingivalis ( P. gingivalis ), an anaerobic bacterial pathogen associated with periodontitis, is known to play a key role in peri-implantitis. To address this issue, the present study examined the antibacterial properties of silver ion (Ag <sup>+</sup> )-coated titanium implants against P. gingivalis and their ability to prevent bone loss. Ag <sup>+</sup> -coated implants, i.e., Ti implants coated with Ag <sup>+</sup> ions on a hydroxyapatite film chelated with inositol hexaphosphate, demonstrated significant antibacterial activity against P. gingivalis in the Ti wire configuration in inhibition zone assays ( n  = 4 per group). Furthermore, in a murine model of ligature-induced peri-implantitis, these implants significantly reduced alveolar bone resorption compared to uncoated titanium controls. This preclinical study suggests that applying an Ag <sup>+</sup> coating to dental implants is an effective strategy for preventing P. gingivalis –induced peri-implantitis. In the control group, bone loss of 19–25% relative to baseline was observed at day 28, whereas the Ag <sup>+</sup> -coated group exhibited only 15–20% bone loss ( n  = 8 per group per time point). These findings suggest the potential of Ag <sup>+</sup> coating as a preventive strategy against peri-implantitis-associated bone loss.

  • Drug Repurposing Screen Identifies Pimozide as a ROS-Inducing Therapy with Anti-tumor Efficacy in HNSCC PDX Models

    Shogo Okazaki, Shintaro Nakamura, Tomoya Soma, Momoko Yoshikawa, Seiji Asoda, Yurika Nakajima, Kenji Tsuchihashi, Mitsuyo Ohmura, Ryo Goitsuka, Kenichi Imai, Hideyuki Saya, Osamu Nagano, Hiroyuki Ozawa

    Cancer Science (Wiley)  117 ( 2 ) 511 - 521 2026.02

    Accepted,  ISSN  1347-9032

    　View Summary

    ABSTRACT

    Redox regulation is a key mechanism supporting tumor survival and an attractive therapeutic target. In this study, we screened 1161 FDA‐approved compounds to identify agents that induce reactive oxygen species (ROS) accumulation in head and neck squamous cell carcinoma (HNSCC) cells. Pimozide, a dopamine D2 receptor antagonist, emerged as the most potent ROS inducer. It selectively suppresses the growth of HNSCC cells with high oxidative stress resistance while exhibiting only modest effects on less resistant cells and normal keratinocytes. Notably, pimozide exhibited anti‐tumor effects as a monotherapy and in combination with paclitaxel at clinically relevant doses. Mechanistic analysis revealed that pimozide rapidly induced ROS accumulation via a mechanism distinct from its known action on dopamine D2 receptors and STAT3/5. To identify markers of ROS‐induced responses, we examined ROS‐responsive genes and found that early growth response 1 (EGR1) was selectively induced in sensitive cells and correlated with pimozide responsiveness. Functional analysis revealed that EGR1 knockdown suppressed pimozide‐induced cytotoxicity, suggesting its role as a functional pharmacodynamic marker of pimozide sensitivity. In a patient‐derived xenograft model of HNSCC, pimozide significantly reduced the tumor burden alone and in combination with paclitaxel. While tumor volume reduction in the combination group was not statistically greater than that in the monotherapy group, fluorescence immunohistochemistry revealed a marked decrease in undifferentiated tumor cells, indicating enhanced therapeutic effects of combination treatment. Taken together, these findings indicate that pimozide is a promising candidate for repurposing as a novel therapeutic agent against HNSCC.

  • DC-STAMP and OC-STAMP cooperatively regulate osteoclast and foreign body giant cell cell-cell fusion

    Fuka Homma, Ryotaro Iwasaki, Makoto Tateyama, Tomoya Soma, Mayu Morita, Makiko Kashio, Taneaki Nakagawa, Takeshi Miyamoto

    Journal of Bone and Mineral Metabolism (Springer Science and Business Media LLC)  44 ( 1 ) 39 - 48 2026.01

    Accepted,  ISSN  0914-8779

    　View Summary

    Abstract

    Introduction

    Osteoclasts and foreign body giant cells (FBGCs) are multi-nuclear cells established by fusion of their mono-nuclear forms. Multi-nucleation via cell–cell fusion is a common characteristic of osteoclasts and FBGCs, and Dendritic Cell-Specific Transmembrane Protein (DC-STAMP) and Osteoclast Stimulatory Transmembrane Protein (OC-STAMP) are both required for the process. Thus, it is thought that DC-STAMP and OC-STAMP interaction likely induces this fusion, but details of these mechanisms are not clear.

    Materials and methods

    We crossed DC-STAMP knockout (KO) with OC-STAMP KO mice to obtain DC-STAMP/OC-STAMP doubly deficient (DKO) mice. Osteoclasts and FBGC common progenitors were isolated from wild-type (WT), DC-STAMP KO, OC-STAMP KO or DKO mice. We then set up 4 co-culture systems: (1) WT with DC-STAMP KO cells, (2) WT with OC-STAMP KO cells, (3) WT with DKO cells, and (4) DC-STAMP KO with OC-STAMP KO cells to induce osteoclast or FBGC formation. We evaluated osteoclast and FBGC formation by TRAP and May–Gruenwald Giemsa staining, respectively. Finally, we performed bone morphometric analysis of WT, DC-STAMP KO, OC-STAMP KO, and DKO mice.

    Results

    Cell–cell fusion occurs normally in co-cultures of DC KO with WT cells, OC KO with WT cells, and DKO with WT cells in both osteoclast and FBGC-inducing conditions. By contrast, co-cultures of DC-STAMP KO with OC-STAMP KO cells did not show cell–cell fusion. Bone morphometric analysis revealed enhanced bone formation in DKO mice.

    Conclusion

    DC-STAMP and OC-STAMP cooperate to promote osteoclast and FBGC cell–cell fusion. DC-STAMP and OC-STAMP doubly deficient mice exhibit increased osteogenesis.

  • A retrospective analysis of outcomes of non-operative therapy for medication-related osteonecrosis of the jaw

    Kanako Munakata, Hidetaka Miyashita, Yuka Yamada, Tomoya Soma, Seiji Asoda, Taneaki Nakagawa

    Journal of Oral and Maxillofacial Surgery (Elsevier BV)  83 ( 12 ) 1549 - 1559 2025.12

    Accepted,  ISSN  0278-2391

    　View Summary

    Background: Limited research is available regarding the role of nonoperative therapy in managing medication-related osteonecrosis of the jaw (MRONJ) as it relates to progression or resolution of disease. Purpose: The study purpose was to estimate the time to MRONJ stage improvement and risk for relapse among patients managed nonoperatively. Study Design, Setting, Sample: This retrospective cohort study included subjects diagnosed with MRONJ at Keio University Hospital between April 2012 and July 2024. Exclusion criteria included absence of a panoramic radiograph, prior operative therapy, or an observation period of less than 3 months. Predictor Variable: The predictor variable was a set of heterogeneous factors including age, sex, disease stage at the initial visit, presence of diabetes, use of steroid, radiographic findings, primary disease, type of bone-modifying agent (BMA), and BMA holiday before improvement. Disease stage after the stage improvement and BMA holiday after the disease improvement were included as covariates for evaluating the risk of relapse. Main Outcome Variable: The main outcome variable was therapeutic response measured as the time between initial treatment and MRONJ stage improvement, which was defined as an improvement of at least one stage. The secondary outcome was relapse measured as the time between maximal therapeutic response measured by MRONJ stage and worsening of the MRONJ stage. Analyses: The Fine-Gray subdistribution hazard model was used to estimate the cumulative incidence function (CIF) of outcomes, and Gray's test was used to compare CIF curves for relapse after stage improvement. Results: The sample was composed of 118 subjects with a mean age of 73.4 (±10.03), 54 (45.8%) were male, and the median interquartile range (IQR) duration of follow-up was 23 (11 to 32.5) months. During the study interval, 84 (71.2%) subjects achieved stage improvement, resulting in a 12-month CIF of 0.594. After achieving maximal therapeutic effect, 34 subjects (40.5%) experienced relapse. Incomplete healing after the stage improvement was associated with a higher risk of relapse (P = .0016), with a CIF of 0.661 at 36 months. Conclusions and Relevance: More than half of the subjects experienced stage improvement within 12 months. Incomplete healing following initial intervention may increase the risk of relapse.

  • A case of cervical necrotizing soft tissue infection in a patient with myelodysplastic/myeloproliferative neoplasms

    Satoshi SHIMOHAMA, Hidetaka MIYASHITA, Tomoya SOMA, Taishi KIMURA, Taneaki NAKAGAWA, Seiji ASODA

    Japanese Journal of Oral and Maxillofacial Surgery (Japanese Society of Oral and Maxillofacial Surgeons)  71 ( 12 ) 585 - 592 2025.12

    Accepted,  ISSN  0021-5163

    　View Summary

    Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are myeloid tumors that combine the characteristics of MDS-like dysplasia, ineffective erythropoiesis of blood cells, and MPN-like hyperplasia of myeloid cells of one or more blood cell lines. We report a case of cervical necrotizing soft tissue infection in a patient with MDS/MPN. A 77-year-old man presented to our hospital with swelling and pain on the right side of his cheek. A blood test of the patient taken by the previous doctor showed an abnormally high white blood cell count of 88,600/μL. Computerized tomography images showed abscesses with gas production primarily in the right submandibular space, which extended to the vicinity of the mediastinum. Under the diagnosis of cervical necrotizing soft tissue infection, percutaneous incisional drainage and debridement were performed under general anesthesia. The patient had a good postoperative course and was discharged from hospital on the 17th day. Patients with MDS/MPN have various clinical symptoms and are easily infected. When treating patients with MDS/MPN, performing perioperative management suited to each patient's condition and considering the development of serious symptoms is essential.

display all >>

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

  • 当科を受診した歯科治療に起因する縦隔気腫の臨床的検討

    木村 大志, 相馬 智也, 加藤 伸, 小林 夏樹, 莇生田 整治, 角田 和之, 中川 種昭

    日本口腔科学会雑誌 ((NPO)日本口腔科学会)  74 ( 2 ) 75 - 76 2025.07

    ISSN  0029-0297

  • 治療抵抗性頭頸部扁平上皮癌を標的とした治療薬の同定

    岡崎 章悟, 吉川 桃子, 相馬 智也, 莇生田 整治, 中島 由梨佳, 今井 健一

    日本歯科医師会雑誌 ((公社)日本歯科医師会)  78 ( 4 ) 384 - 384 2025.07

    ISSN  0047-1763

  • 炭酸アパタイトを使用したインプラント周囲炎の再生療法に関する観察研究

    宮下 英高, 堀江 伸行, 森川 曉, 古澤 春佳, 柴崎 竣一, 相馬 智也, 宗像 花楠子, 小高 利絵, 中川 種昭, 莇生田 整治

    顎顔面補綴 ((一社)日本顎顔面補綴学会)  48 ( 1 ) 55 - 55 2025.06

    ISSN  0389-4045

  • Immobilization of silver ions on hydroxyapatite-coated titanium using inositol phosphate and its anti-bacterial property

    近藤葵, ZHU X.Y., 鈴木来, 宮下英高, 相馬智也, 那須真奈, 中川種昭, 森川暁, 相澤守

    日本セラミックス協会年会講演予稿集(Web) 2025 2025

  • An observational study on regenerative therapy for peri-implantitis using carbonate apatite

    宮下英高, 堀江伸行, 森川曉, 古澤春佳, 柴崎竣一, 相馬智也, 宗像花楠子, 小高利絵, 中川種昭, 莇生田整治

    Japanese Journal of Maxillo Facial Implants ((公社)日本顎顔面インプラント学会)  23 ( 3 ) 148 - 148 2024.11

    ISSN  1347-894X

display all >>

Page Top ▲

Presentations 【 Display / hide 】

  • 腹部大動脈瘤ステント留置患者の慢性DICに起因した抜歯後出血の1例

    磐田翔, 相馬智也, 木村大志, 宗像花楠子, 山田有佳, 宮下英高, 莇生田整治

    [Domestic presentation]  第221回（公社）日本口腔外科学会関東支部学術集会 (東京都 東京歯科大学水道橋キャンパス) , 

    2026.05
    , 

    Oral presentation (general)

  • A case of extraction of three fourth molars

    Mikito Okada, Tomoya Soma, Kanako Munakata, Takahiro Asano, Taneaki Nakagawa, Seiji Asoda

    [Domestic presentation]  The 80th Annual Meeting of the Japanese Stomatological Society (新潟県　朱鷺メッセ　新潟コンベンションセンター) , 

    2026.04
    , 

    Oral presentation (general)

  • Inhibition of Medication-Related Osteonecrosis of the Jaw Through Control of Inflammatory Cytokines: Aiming for Clinical Application from Mouse Models

    Tomoya Soma，Mayu Morita，Kanako Munakata，Hidetaka Miyashita， Takeshi Miyamoto，Seiji Asoda，Taneaki Nakagawa

    [Domestic presentation]  The 80th Annual Meeting of the Japanese Stomatological Society (新潟県　朱鷺メッセ　新潟コンベンションセンター) , 

    2026.04
    , 

    Symposium, workshop panel (public)

  • オスラー病を有する患者の智歯抜歯経験

    藤井康太, 木村大志, 相馬智也, 阪口友梨, 莇生田整治, 中川種昭

    [Domestic presentation]  第35回日本有病者歯科医療学会総会・学術大会 (東京都 東京国際フォーラム) , 

    2026.03
    , 

    Oral presentation (general)

  • Tongue Reduction for Lymphangiomatous Macroglossia: a case report

    Yuri Sakaguchi, Kanako Munakata, Tomoya Soma, Taishi Kimura, Yuka Yamada, Hidetaka Miyashita, Taneaki Nakagawa, Seiji Asoda

    [Domestic presentation]  The 44st Annual Meeting of Japanese Society of Oral Oncology (栃木県 ライトキューブ宇都宮) , 

    2026.01
    , 

    Oral presentation (general)

display all >>

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

  • 破骨細胞融合因子DC-STAMP/OC-STAMPの制御メカニズムの解明

    2026.04
    -
    2029.03

    日本学術振興会, Grants-in-Aid for Scientific Research, Grant-in-Aid for Early-Career Scientists, Principal investigator

  • 力学的負荷を加えた多重障害インプラント周囲炎モデルの構築

    2024.10
    -
    2025.10

    公益社団法人日本顎顔面インプラント学会 , 第3回赤坂庸子若手研究奨励基金, Coinvestigator(s)

  • 進行口腔扁平上皮癌に対するPCE導入化学療法による縮小手術の可能性についての検討

    2023.06
    -
    2024.08

    公益社団法人 日本口腔外科学会, 2022・2023年度研究助成「次世代若手臨床研究推進プロジェクト」, Coinvestigator(s)

  • ビタミンD誘導体による難治性骨破壊性疾患の治療への応用

    2023.04
    -
    2026.03

    日本学術振興会, Grants-in-Aid for Scientific Research, Grant-in-Aid for Early-Career Scientists, Principal investigator

    　View Summary

    口腔顎顔面外科領域では口腔内疾患の多くに骨吸収や骨破壊などを伴う炎症性疾患が多く認められる。ビスフォスフォネート製剤などによる骨吸収製剤の副作用である薬剤関連顎骨壊死も炎症を伴う骨破壊性疾患のひとつである。申請者はこれまで、ビスフォスフォネート製剤を投与したマウスモデルを用い、炎症性サイトカインが、骨壊死の発生や破骨細胞を介した骨破壊を引き起こすことを明らかにした。近年、ビタミンDの抗炎症作用が注目されており、そこで本研究では、炎症を伴う難治性骨破壊性疾患に対するビタミンDの分子メカニズムを解明し、新たな治療方法の確立を目指したい。

  • C

    2022.04
    -
    2025.03

    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), Grant-in-Aid for Scientific Research (C), Coinvestigator(s)

    　View Summary

    「口から食べること」による医学的効果は大きく、残存歯数が少ないほど、認知症の発症リスクが高くなるという負の関連を示す論文も公表され、健康寿命の延伸を果たすために、健全な口腔咀嚼機能の改善や構築は大きな課題であると考えられる。超高齢社会において「口から食べることを支援することによる健康寿命の延伸」に貢献するべく、安全な骨代謝機能と抗菌機能を兼ね備えた歯周組炎およびインプラント周囲炎骨再生材料を開発する。また、同様の抗菌システムを備えたインプラント周囲炎抵抗性デンタルインプラントシステムの開発を目指す。

display all >>

Page Top ▲

Awards 【 Display / hide 】

  • JBMM Excellent Paper Award

    Tomoya Soma, Ryotaro Iwasaki, Yuiko Sato, Tami Kobayashi, Satoshi Nakamura, Yosuke Kaneko, Eri Ito, Hiroyuki Okada, Hisato Watanabe, Kana Miyamoto, Morio Matsumoto, Masaya Nakamura, Seiji Asoda, Hiromasa Kawana, Taneaki Nakagawa, Takeshi Miyamoto, 2024.07, The Japanese Society for Bone and Mineral Research, Tooth extraction in mice administered zoledronate increases inflammatory cytokine levels and promotes osteonecrosis of the jaw

    Type of Award： Award from Japanese society, conference, symposium, etc.

  • 第75回日本口腔科学会学術集会 Rising Scientist賞

    相馬智也, 森田麻友, 岩崎良太郎, 莇生田整治, 河奈裕正, 中川種昭, 宮本健史, 2021.05, ゾレドロネート投与と侵襲的歯科処置は，炎症性サイトカインを上昇させ，骨吸収薬剤関連顎骨壊死を誘発する

    Type of Award： Award from Japanese society, conference, symposium, etc.

  • 第5回日本骨免疫学会 優秀演題賞

    相馬智也, 森田麻友, 岩崎良太郎, 中川種昭, 宮本健史, 2019.06, 骨吸収抑制薬による薬剤関連顎骨壊死には炎症性サイトカインの上昇が必須である

    Type of Award： Award from Japanese society, conference, symposium, etc.

  • 日本歯科医学会ポスター賞（若手研究者部門）

    岡﨑章悟, 吉川桃子, 相馬智也, 莇生田整治, 中島由梨佳, 今井健一, 2025.09, 第25回日本歯科医学会学術大会, 治療抵抗性頭頸部扁平上皮癌を標的とした治療薬の同定

    Type of Award： Award from Japanese society, conference, symposium, etc.

  • 第36回日本小児口腔外科学会優秀発表賞（ポスター発表）

    永田香織, 臼田慎, 二宮真希, 長嶺宏樹, 佐藤晃子, 赤田晋也, 遠藤友樹, 相馬智也, 莇生田整治, 木津英樹, 2024.11, 第36回日本小児口腔外科学会総会・学術大会, 小児萌出遅延歯に対する開窓・牽引療法の検討

display all >>

Page Top ▲
 

Memberships in Academic Societies 【 Display / hide 】

  • Sigma Xi (Scientific Research Honor Society), Full Membership, 

    2026.06
    -
    Present

  • Asian Association of Oral and Maxillofacial Surgeons, 

    2018.01
    -
    Present

  • Japanese Society of Oral and Maxillofacial Surgeons, 

    2009.08
    -
    Present

  • Japan Society for Head and Neck Cancer, 

    2026.02
    -
    Present

  • Japanese Society of Pediatric Oral and Maxillofacial Surgery, 

    2022.09
    -
    Present

display all >>

Page Top ▲